Higher Prevalence of Long COVID Observed in Cancer Survivors: Insights from a US Nationwide Survey, 2025, Wang et al

[forestglip]

Higher Prevalence of Long COVID Observed in Cancer Survivors: Insights from a US Nationwide Survey

Lingchen Wang, Wei Yang

Background
Cancer and cancer treatments can weaken the body's immune system, making cancer patients particularly vulnerable to COVID-19. While evidence suggests that cancer patients may be at increased risk for severe outcomes after COVID-19 infection, there is a lack of population-based studies comparing long COVID prevalence between cancer survivors and non-cancer individuals.

Methods
We utilized data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS), analyzing a sample of 120,658 U.S. adults who had tested positive for COVID-19. Long COVID was defined as the presence of COVID-19 symptoms lasting three months or longer. The weighted prevalence of long COVID was compared between cancer survivors and non-cancer individuals. Crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Multiple imputation was employed to address missing data on COVID-19 vaccination.

Results
Among 17,362 cancer survivors who tested positive for COVID-19, 4,009 reported having long COVID (weighted prevalence = 24.0%), compared to a weighted prevalence of 21.6% in non-cancer individuals (p < 0.001). After controlling for covariates and accounting for the complex sampling design, the adjusted OR was 1.17 (95% CI = 1.06–1.30, p = 0.002). In participants under 45 years old, cancer survivors had a notably higher prevalence of long COVID compared to non-cancer individuals (32.1% vs. 21.3%, p < 0.001), with an adjusted OR of 1.33 (95% CI = 1.07–1.66, p = 0.012). In participants aged 45 and above, the prevalence difference was not significant (22.7% vs. 21.9%, p = 0.324), with an adjusted OR of 1.14 (95% CI = 1.02–1.27, p = 0.024). Regarding the association of COVID-19 vaccination with long COVID, four or more doses were linked to a significant reduced odds of long COVID among cancer survivors (adjusted OR=0.55, 95%CI = 0.34-0.88, p = 0.013).

Conclusions
Cancer survivors are observed to have higher odds of developing long COVID, particularly younger survivors. The association of COVID-19 vaccination with long COVID varies between cancer survivors and non-cancer individuals, with cancer survivors requiring more doses to achieve significant reduction in the odds of long COVID.

Link (Annals of Epidemiology) [Paywall]

 

[Utsikt]

I’m surprised it tool cancer five years to catch on. Maybe this will lead to more funding?

 

[SNT Gatchaman]

A total of 120,658 participants were included in this study, with 17,362 in the cancer group (10.1%, 95% CI = 9.8%–10.5%) and 103,296 in the noncancer group (89.9%, 95% CI = 89.5%–90.2%).

Significant differences were observed between the groups across various characteristics. Specifically, compared to the non-cancer group, the cancer group had a higher proportion of older participants (p < 0.001), a greater proportion of females (p < 0.001), more Non-Hispanic Whites (p < 0.001), a higher level of education (p < 0.001), and a lower rate of those who have never married (p < 0.001). Additionally, the cancer group had a higher proportion of participants with health insurance (p < 0.001), a greater proportion of BMI above the normal range (p < 0.001) and a greater prevalence of smoking history (p < 0.001). Regarding chronic health conditions, the cancer group exhibited higher prevalences of COPD (p < 0.001), diabetes (p < 0.001), current asthma (p < 0.001), heart disease (p < 0.001), and stroke history (p < 0.001) compared to the non-cancer group. Notably, a higher proportion of individuals in the cancer group had received three or more doses of the COVID-19 vaccine compared to those in the noncancer group (p < 0.001).